Monitoring Symptoms in Myasthenia Gravis Using Wearable Sensors and Digital Assessments
Tests wearable sensors and home digital checks to monitor symptoms in adults with myasthenia gravis.
Plain-language title generated from the registry record
Registry title: Multi-Modal Monitoring of Disease Symptoms in Myasthenia Gravis
Key facts
- Where
- Boston, United StatesSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07224386, who can take part
Where in United States
- Massachusetts General Hospital, Neuromuscular Diagnostic CenterBoston, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- BioSensics
- Trial code
- NCT07224386
- Record updated
- 4 November 2025
- Original description
Evaluate the feasibility of using digital health technologies to monitor symptoms in myasthenia gravis (MG).Read full original descriptionShow less
Multi-Modal Monitoring of Disease Symptoms in Myasthenia Gravis
Evaluate the feasibility of using digital health technologies to monitor symptoms in myasthenia gravis (MG).
Study subjects will be screened and enrolled at Massachusetts General Brigham Hospital to participate in this 12 month observational study. Study subjects will be asked to wear multiple wearable sensors to monitor their physical activity and PPG during daily activities. Participants will also complete speech, video, and ePRO and eCOA digital assessments at home and during study visits.
The primary objective for this observational study is to measure the correlation of sensor-derived measures of physical activity to MG-specific ratings of MG-ADL, QMG, MGC, and Neuro-QoL Fatigue
Inclusion: Autoimmune MG with or without history of thymoma, MGFA severity Class IIa/b, IIIa/b or IVa/b at the screening visit; Diagnosed gMG through ONE of the following methods:; Positive acetylcholine receptor antibody (AChR Ab) test; Positive muscle specific kinase receptor antibody (MuSK Ab) test; Positive LRP4 antibody and abnormal neuromuscular transmission demonstrated by single-fiber electromyography (SFEMG) or repetitive nerve stimulation (RNS) OR has maintained a positive response to treatments such as AChE inhibitors, IVIG/PLEX, FcRn antagonists or C5 inhibitors; Abnormal neuromuscular transmission demonstrated by single-fiber electromyography (SFEMG) or repetitive nerve stimulation (RNS) OR has maintained a positive response to treatments such as AChE inhibitors, IVIG/PLEX, FcRn antagonists or C5 inhibitors; Physically and cognitively able to provide informed consent and adhere to the protocol, as determined by the investigator's judgment; Ambulatory status defined as the ability to walk a distance of 10 meters independently, with or without the use of an assistive device; Male or female, between the ages of 18 years old and 80 years old; Speaks and reads English fluently.
Exclusion: Concurrent participation in an interventional clinical trial (observational studies, biomarker studies and registries are acceptable); Any significant medical, laboratory, or psychiatric condition that, in the judgment of the investigators, would potentially interfere with the ability to participate in the study; Inability to engage in activities that are essential for independent living, such as dressing, bathing, toileting, or eating independently; Neurological or orthopedic problems independent of myasthenia which significantly affect gait and ADLs in the investigator's judgement; Residence in long-term care centers or institutions, nursing facilities, skilled nursing facilities, or recipients of hospice care, or incarceration; MGFA severity class I or V (MG crisis); Pregnant women.